Drug Profile


Alternative Names: CGT003; CGT021; E2F Decoy; E2F transcription factor decoy

Latest Information Update: 05 Apr 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Brigham and Womens Hospital; Stanford University
  • Class Oligonucleotides; Vasodilators
  • Mechanism of Action Cdc2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery restenosis; Vascular graft occlusion

Most Recent Events

  • 28 Mar 2005 Discontinued - Phase-I for Coronary artery restenosis in Japan (unspecified route)
  • 28 Mar 2005 Discontinued - Phase-II for Coronary artery restenosis in Germany (unspecified route)
  • 28 Mar 2005 Discontinued - Phase-III for Coronary artery restenosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top